What is a stock summary page? Click here for an overview.
Business Description
Grifols SA
ISIN : ES0171996087
Share Class Description:
CHIX:GRFe: Ordinary Shares - Class ADescription
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.1 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 1.71 | |||||
| Debt-to-EBITDA | 9.78 | |||||
| Interest Coverage | 2.29 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.94 | |||||
| Beneish M-Score | -2.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.6 | |||||
| 3-Year EBITDA Growth Rate | 16.4 | |||||
| 3-Year EPS without NRI Growth Rate | -2.5 | |||||
| 3-Year FCF Growth Rate | 23.6 | |||||
| 3-Year Book Growth Rate | 2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 34.89 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.93 | |||||
| 9-Day RSI | 42.64 | |||||
| 14-Day RSI | 39.99 | |||||
| 3-1 Month Momentum % | 5.84 | |||||
| 6-1 Month Momentum % | -4.83 | |||||
| 12-1 Month Momentum % | 9.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.66 | |||||
| Quick Ratio | 1.01 | |||||
| Cash Ratio | 0.46 | |||||
| Days Inventory | 376.45 | |||||
| Days Sales Outstanding | 50.26 | |||||
| Days Payable | 90.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 12.5 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.73 | |||||
| Operating Margin % | 17.07 | |||||
| Net Margin % | 2.43 | |||||
| FCF Margin % | 9.5 | |||||
| ROE % | 2.44 | |||||
| ROA % | 0.64 | |||||
| ROIC % | 2.39 | |||||
| 3-Year ROIIC % | 4.56 | |||||
| ROC (Joel Greenblatt) % | 11.66 | |||||
| ROCE % | 4.39 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 40.95 | |||||
| Forward PE Ratio | 14.55 | |||||
| PE Ratio without NRI | 38.79 | |||||
| Shiller PE Ratio | 9.48 | |||||
| PS Ratio | 1.01 | |||||
| PB Ratio | 0.93 | |||||
| Price-to-Free-Cash-Flow | 10.33 | |||||
| Price-to-Operating-Cash-Flow | 6.08 | |||||
| EV-to-EBIT | 20.85 | |||||
| EV-to-Forward-EBIT | 13.53 | |||||
| EV-to-EBITDA | 16.44 | |||||
| EV-to-Forward-EBITDA | 9.3 | |||||
| EV-to-Revenue | 3.04 | |||||
| EV-to-Forward-Revenue | 1.9 | |||||
| EV-to-FCF | 31.66 | |||||
| Price-to-GF-Value | 0.58 | |||||
| Price-to-Projected-FCF | 0.75 | |||||
| Price-to-Median-PS-Value | 0.29 | |||||
| Earnings Yield (Greenblatt) % | 4.8 | |||||
| FCF Yield % | 10.31 | |||||
| Forward Rate of Return (Yacktman) % | -9.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Grifols SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5,586.676 | ||
| EPS (TTM) (€) | 0.197 | ||
| Beta | 2.19 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.27 | ||
| Volatility % | 44.19 | ||
| 14-Day RSI | 39.99 | ||
| 14-Day ATR (€) | 0.145332 | ||
| 20-Day SMA (€) | 8.2706 | ||
| 12-1 Month Momentum % | 9.04 | ||
| 52-Week Range (€) | 7.399 - 11.255 | ||
| Shares Outstanding (Mil) | 680.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Grifols SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Grifols SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Grifols SA Frequently Asked Questions
What is Grifols SA(CHIX:GRFe)'s stock price today?
The current price of CHIX:GRFe is €8.15. The 52 week high of CHIX:GRFe is €11.26 and 52 week low is €7.40.
When is next earnings date of Grifols SA(CHIX:GRFe)?
The next earnings date of Grifols SA(CHIX:GRFe) is 2025-05-14 Est..
Does Grifols SA(CHIX:GRFe) pay dividends? If so, how much?
Grifols SA(CHIX:GRFe) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers